Expert Financial Analysis and Reporting

Recent Reports

• Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96) (0)

Recent Blogs

• Comment on the Sharp Correction in Small Biopharma Stocks (0)
• Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport (CYRX, Buy, $9.05) (0)
• Brief Updates on Key Buy Recommendations (0)
• Bristol-Myers-Squibb: Negative Market Reaction to Celgene Acquisition is a Buying Opportunity (BMY, Buy, $45.17) (0)
• Portola: Critical Upcoming Catalysts Have the Potential to Cause a Sharp Upward Move in the Stock (PTLA,  Buy, $29.19) (0)
• Portola: Approval of Gen 2 Manufacturing Process for AndexXa is a Significant Positive (PTLA, Buy, $18.75) (0)
• Update on Currently Recommended Stocks of SmithOnStocks.com (0)
• Portola Pharmaceuticals: 2019 Is All About the Sales Trajectory of AndexXa (PTLA, $15.46, Buy) (0)
• Novartis Releases Three Month Interim Data for JULIET Trial of CTL-019 in r/r DLBCL (0)
• Northwest Biotherapeutics: Non-Dilutive Financing Provides Major Boost to Investment Outlook (NWBO, $0.25, Buy) (0)
• FDA Announces July 12 AdCom Meeting for CTL-019: Thoughts on How This Might Affect Investor Perceptions of Kite (KITE, Neutral, $80.25) and Cryoport (CYRX, Buy, $3.89) (0)

Social Feeds

• • $ CYRX Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport… https://t.co/TQ4KFbritg, Jan 09
  • $PTLA Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96) https://t.co/76AuWyEbFH, Jan 09
  • $BMY Negative Market Reaction to Celgene Acquisition is a Buying Opportunity https://t.co/0aybnueJbx, Jan 04
  • $nwbo $46 million non-dilutive financing provides major boost to investment outlook. See my report. https://t.co/pidvWRoYUR, Dec 17
  • $cyrx Cryoport raises a $25 million warchest for acquisiitons https://t.co/OyAt5ZlY87, Dec 17